P3 cap modified Phe*-Ala series BACE inhibitors.

Shu-Hui Chen, Jason Lamar, Deqi Guo, Todd Kohn, Hsiu-Chiung Yang, James McGee, David Timm, Jon Erickson, Yvonne Yip, Patrick May, James McCarthy

Index: Bioorg. Med. Chem. Lett. 14(1) , 245-50, (2004)

Full Text: HTML

Abstract

With the aim of reducing molecular weight and adjusting log D value of BACE inhibitors to more favorable range for BBB penetration and better bioavailability, we synthesized and evaluated several series of P3 cap modified BACE inhibitors obtained via replacement of the P3NHBoc moiety as seen in 3 with other polar functional groups such as amino, hydroxyl and fluorine. Several promising inhibitors emerging from this P3 cap SAR study (e.g., 15 and 19) demonstrated good enzyme inhibitory potencies (BACE-1 IC(50) <50 nM) and whole cell activities (IC(50) approximately 1 microM).